• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    SC 13G/A 1 polar-brkr093024a3.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    Schedule 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*



    BRUKER CORPORATION

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    116794108

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  116794108
     Schedule 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital Holdings Plc
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    317,928
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    317,928
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    317,928
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.21%
    12
    TYPE OF REPORTING PERSON
     
    HC

     


     

    CUSIP No.  116794108
     Schedule 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital LLP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    317,928
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    317,928
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    317,928
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.21%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

     

    CUSIP No. 116794108
     Schedule 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    BRUKER CORPORATION

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    40 Manning Road

    Billerica, MA 01821

    Item 2.(a) Name of Person Filing:

     

    Polar Capital Holdings Plc

    Polar Capital LLP

     

    Item 2.(b,) Address of Principal Business Office:

     

    16 Palace Street

    London, SW1E 5JD

     

    Item 2.(c) Citizenship:

     

    United Kingdom

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.01 par value per share (the “Shares”)

     

    Item 2.(e) CUSIP No.:

    116794108

     

    CUSIP No.  116794108
     Schedule 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 116794108
     Schedule 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1:

    Polar Capital Holdings Plc

    (a) Amount beneficially owned: 317,928

    (b) Percent of class: 0.21%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 317,928

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 317,928

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    Polar Capital LLP

    (a) Amount beneficially owned: 317,928

    (b) Percent of class: 0.21%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 317,928

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 317,928

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    * Based on 151,394,441 shares outstanding as reported in the Issuer's Form 10-Q on August 9, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [x].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Information for each Subsidiary is incorporated on the respective cover pages.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 116794108
     Schedule 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 13, 2024

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           

     

     
    CUSIP No. 116794108
     Schedule 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 13, 2024

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer

           
    Get the next $BRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    2/14/2024$60.00 → $90.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Linton William A exercised 10,000 shares at a strike of $24.00, increasing direct ownership by 21% to 58,723 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      4/24/25 4:15:05 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      3/11/25 4:11:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Francis Laura

      3 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:40:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Bruker with a new price target

      Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

      12/19/24 7:30:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • UBS initiated coverage on Bruker with a new price target

      UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

      12/10/24 8:26:42 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker upgraded by Goldman with a new price target

      Goldman upgraded Bruker from Sell to Neutral and set a new price target of $60.00

      12/5/24 7:35:59 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/14/24 1:28:29 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/13/24 6:01:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/12/24 11:54:03 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Bruker Corporation

      10-Q - BRUKER CORP (0001109354) (Filer)

      5/7/25 4:04:14 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      5/7/25 7:00:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Bruker Corporation

      DEF 14A - BRUKER CORP (0001109354) (Filer)

      4/11/25 4:28:51 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      3/11/25 4:11:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:23:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      11/19/24 4:07:19 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Financials

    Live finance-specific insights

    See more
    • Bruker Reports First Quarter 2025 Financial Results

       Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's

      5/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces First Quarter 2025 Preliminary Revenue

      Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net

      4/11/25 8:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Quarterly Dividend

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microsc

      2/21/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Reports First Quarter 2025 Financial Results

       Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's

      5/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025

      Advancements include CosMx® 2.0 upgrade; CosMx same-slide multiomics; and multiomics capabilities on the nCounter® platform Bruker Corporation (NASDAQ:BRKR) announced today that it will unveil significant advancements in spatial biology and multiomics research at the 2025 American Association for Cancer Research (AACR) General Meeting. These new advancements build upon the innovations announced at AGBT, including launch of CosMx WTX assay for subcellular spatial imaging of the whole transcriptome, the PaintScape™ platform for visualization of 3D genome architecture and chromosomal structure in single cells, the PowerOMX™ engine for streamlined spatial proteomics analysis on the CellScape™

      4/25/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis

      A Compact Benchtop Optofluidic System with Lower Cost of Ownership for Broader Research Accessibility Bruker Corporation (NASDAQ:BRKR) today announced the launch of the Beacon Discovery™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop system offers an accessible entry point into live single-cell functional analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424150192/en/Beacon Discovery – an accessible, compact system for live single-cell functional analysis Building on Bruker's proprietary Opto-Electrical Positioning (OEP) technology and sc

      4/24/25 7:30:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    See more
    • Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

      ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

      4/23/25 6:15:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

      Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

      4/4/24 8:11:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials